Recent Updates — EVAX

Evaxion A/S announced three-year follow-up data from its phase 2 trial of the personalized cancer vaccine EVX-01 in patients with advanced melanoma. The results demonstrated that EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent specific T-cell responses. Sustained T-cell responses were observed during the third year of treatment as monotherapy, and all patients maintained their clinical response with no tumor progression through the third year. The data will be presented at the ESMO 2026 Congress on October 24, 2026. Evaxion A/S is a clinical-stage TechBio company developing AI-powered immunotherapies for cancer.

Evaxion A/S announced three-year follow-up data from its phase 2 trial of the personalized cancer vaccine EVX-01 in patients with advanced melanoma. All patients maintained their clinical responses observed at two-year follow-up, with no tumor progression reported during the third year when patients received EVX-01 as stand-alone therapy. The findings supplement previous two-year data showing a 75% Objective Response Rate and durable benefit, with 92% of patients still responding at that mark. Evaxion is a clinical-stage TechBio company developing AI-powered immunotherapies for cancer.

Evaxion A/S announced it will present new immune data for its personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in November 2026. The presentation includes both oral and poster formats detailing systemic immunomodulatory effects from a phase 2 trial combining EVX-01 with pembrolizumab in advanced melanoma patients. Previous two-year data showed an Objective Response Rate of 75%, with four out of sixteen patients achieving complete response, while nine percent maintained durable clinical benefit without relapse. The company will also provide three-year clinical updates at the ESMO 2026 congress on October 24, 2026. Evaxion A/S is a clinical-stage biotechnology company specializing in AI-driven immunotherapy and vaccine development for cancer.

Evaxion A/S sold 681,268 American Depositary Shares (ADSs) at an average price of USD $3.1987 per ADS through its at-the-market offering with Jones Trading Institutional Services LLC. Net proceeds from the transaction totaled $2,113,767 after deducting fees and expenses. The company registered a share capital increase of nominal DKK 8,515,850 with the Danish Business Authority, effective August 24, 2026, bringing total nominal share capital to DKK 112,768,539. Articles of Association were amended to reflect these changes. Evaxion A/S operates in the biotechnology industry, focusing on developing cancer vaccines.

Evaxion A/S reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to $4.8 million in the same period last year. Cash and cash equivalents stood at $14.0 million as of June 30, 2026, providing a runway into the second half of 2027. The company announced business updates including upcoming presentations of three-year clinical data for EVX-01 at ESMO Congress 2026 and new preclinical data for EVX-04 and EVX-V1. Evaxion A/S is a clinical-stage biotechnology company developing AI-powered vaccines for cancer and infectious diseases.